Showing 1811-1820 of 2652 results for "".
- Supply Chain Snags Blamed For Cut to Pfizer COVID-19 Vaccine Rollout This Year: Reporthttps://modernod.com/news/supply-chain-snags-blamed-for-cut-to-pfizer-covid-19-vaccine-rollout-this-year-report/2478626/Pfizer and BioNTech expect to ship only half of the 100 million doses of COVID-19 vaccine they had originally targeted for worldwide delivery this year because of hurdles encountered with the supply chain, according to a report in The Wall Street Journal on Thursday. A person directly in
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede
- Zhaoke Ophthalmology Announces First Patient Completes 3-Year Enrollment in Phase 3 Myopia Trialhttps://modernod.com/news/zhaoke-ophthalmology-announced-first-patient-completes-3-year-enrollment-in-phase-3-myopia-trial/2478533/Zhaoke Ophthalmology Pharmaceutical has announced that the first patient has completed 3-year enrollment in the phase 3 CHAMP (Childhood Atropine for Myopia Progression) study carried out by its partner, Nevakar. The CHAMP Study is an FDA drug trial that evaluates the ability of its lead compound
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- Concerns Over Surgical Waste Are Clouding Future of Single-Use Device Markethttps://modernod.com/news/concerns-over-surgical-waste-are-clouding-future-of-single-use-device-market/2478423/The global single-use surgical device market has shown steady growth over several decades, reaching a peak of $3.4 billion in 2019, but growing concerns over the amount of waste created by disposable surgical devices have raised questions about future growth prospects, according to a Market Scope
- A 25-Year-Old Man Becomes First in the U.S. to Contract Coronavirus Twicehttps://modernod.com/news/a-25-year-old-man-becomes-first-in-the-u-s-to-contract-coronavirus-twice/2478412/A 25-year-old man in the U.S. state of Nevada has contracted the coronavirus on two separate occasions, a study in the Lancet Infectious Diseases journal showed
- BVI Expands Malosa Single-Use Instrument Range in the UShttps://modernod.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/BVI announced the extension of its Malosa range of single-use ophthalmic instruments in the US. The US Malosa portfolio will now include specialty instruments for use in corneal refractive surgery, complementing the existing single-use product range for cataract, oculoplastic, and office-based pr
- Safer and More Effective Glaucoma Surgical Options Will Drive Surgery Device Treatment Penetration Over Next Five Yearshttps://modernod.com/news/safer-and-more-effective-glaucoma-surgical-options-will-drive-surgery-device-treatment-penetration-over-next-five-years/2478181/Expanding use of surgical devices in patients with all stages of glaucoma will increase the role of surgery in the glaucoma treatment paradigm over the next 5 years, according to a Market Scope report. There are four FDA-approved minimally invasive glaucoma surgery (MIGS) stents in the US: